Anthony Morales, MD
Interventional Cardiology · Slidell, LANPI 1871576215
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 295 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by Pfizer at 30.3% of the total. That places this record below the midpoint for interventional cardiology clinicians in LA, where the typical reported total is $9,970.
Across 295 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Novartis$542
- Johnson & Johnson$519
- Merck$273
- E.r. Squibb & Sons, L.L.C.$265
- Abbott$256
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,998100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 93 | $1,517 |
| Novartis | 34 | $542 |
| Johnson & Johnson | 36 | $519 |
| Merck | 16 | $273 |
| E.r. Squibb & Sons, L.L.C. | 15 | $265 |
| Abbott | 13 | $256 |
| Boehringer Ingelheim | 14 | $225 |
| Amgen | 14 | $209 |
| Esperion Therapeutics, Inc. | 9 | $172 |
| AstraZeneca | 8 | $122 |
| Baxter Healthcare | 3 | $107 |
| Irhythm Technologies, Inc. | 5 | $90 |
| Kowa Pharmaceuticals America, Inc. | 5 | $86 |
| Lundbeck LLC | 4 | $83 |
| Novo Nordisk | 4 | $78 |
| Medtronic(2 entities) | 3 | $66 |
| Edwards Lifesciences | 2 | $65 |
| Daiichi Sankyo Inc. | 2 | $56 |
| Scpharmaceuticals Inc. | 3 | $56 |
| Gilead | 4 | $53 |
| Kestra Medical Technology Services, Inc. | 2 | $50 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Philips North America LLC | 1 | $22 |
| Atricure, Inc. | 1 | $22 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Terumo Medical Corporation | 1 | $15 |
How this compares
$5,009 in reported general payments places this provider in the 30th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $59,188 |
| Metoprolol Succinate | 74 | $1,012 |
| Alprazolam | 205 | $678 |
| Irbesartan | 23 | $563 |
| Verapamil ErVerapamil Hcl | 11 | $480 |
| Atorvastatin Calcium | 30 | $409 |
| Olmesartan Medoxomil | 19 | $385 |
| Clonazepam | 61 | $351 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $305 |
| Zolpidem Tartrate | 76 | $301 |
| Losartan Potassium | 26 | $243 |
| Hydralazine Hcl | 16 | $207 |
| Terazosin Hcl | 20 | $203 |
| Carvedilol | 17 | $177 |
| Rosuvastatin Calcium | 26 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,517 | $59,18849 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Slidell
- Omer IftikharSlidell$22K
- Sergio BarriosSlidell$15K
- Craig WalkerHouma$5M
- Denzil MoraesBaton Rouge$901K
- Ankur LodhaLafayette$640K
- Rajan PatelNew Orleans$517K
- Agostino IngraldiLafayette$315K
- Steven BaileyShreveport$305K
- James JenkinsNew Orleans$235K
- Louis SalvaggioLafayette$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.